1525 - Updated Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results From the Ongoing Phase 1 CaDAnCe-101 Study

Primary Author / Presenter(s)

Stephan Stilgenbauer, MD

Professor of Medicine, Medical Director
Division of CLL, Internal Medicine III, Ulm University
Ulm, Baden-Wurttemberg, Germany

Co-Author(s)

Lydia Scarfò

Assistant Professor
Università Vita Salute and IRCCS Ospedale San Raffaele
Milano, Lombardia, Italy
RP

Ricardo D. Parrondo, MD

Mayo Clinic
Jacksonville, Florida, United States
Meghan C. Thompson

Fellow in Hematology & Medical Oncology
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
New York, New York, United States
AF

Anna Maria Frustaci, MD

ASST Grande Ospedale Metropolitano Niguarda
Milano, Italy
John Allan, MD

Assistant Prof Medicine
Weill Cornell Medicine
New York, New York, United States
Paolo Ghia, MD, PhD

Professor of Medical Oncology
Università Vita Salute and IRCCS Ospedale San Raffaele
Milano, Lombardia, Italy
IM

Irina Mocanu

Institute of Oncology, ARENSIA Exploratory Medicine, Düsseldorf, Germany
Düsseldorf, Nordrhein-Westfalen, Germany
CT

Constantine S. Tam, MD, MBBS

Consultant Haematologist
Alfred Hospital and Monash University
Melbourne, Victoria, Australia
DR

Damien Roos-Weil, MD, PhD

Pitié-Salpêtrière Hospital
Paris, France
JT

Judith Trotman

Concord Repatriation General Hospital, University of Sydney, Concord, NSW, Australia
Concord, New South Wales, Australia
Inhye E. Ahn, MD

Assistant Professor
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
NL

Nicole Lamanna, MD

Associate Professor
Columbia University Medical Center
New York, New York, United States
LX

Linlin Xu, PhD

Senior Scientist
BeOne Medicines Ltd, San Carlos, CA, USA
San Carlos, California, United States
KB

Kunthel By

BeOne Medicines Ltd
San Carlos, California, United States
SF

Shannon Fabre

BeOne Medicines Ltd
San Carlos, California, United States
DP

Daniel Persky, MD

BeOne Medicines Ltd, San Carlos, CA, USA
San Carlos, California, United States
AA

Amit Agarwal

BeOne Medicines Ltd
San Carlos, California, United States
JS

John Seymour, MBBS, PhD, FRACP

Director, Department of Haematology
Peter MacCallum Cancer Centre & Royal Melbourne Hospital
Melbourne, Victoria, Australia